Stradling Counsels Ligand Pharma in $3 Million Investment in Dianomi Therapeutics

February 2019

Stradling advised Ligand Pharmaceuticals Inc., a San Diego-based biopharmaceutical company, in its investment in Dianomi Therapeutics Inc. Ligand announced the deal closed Feb. 5. Dianomi is a biopharmaceutical company in Madison, Wisconsin that aims to improve treatments for many diseases. The company also aims to boost therapies for inflammatory conditions, such as osteoarthritis and pain.

The Stradling lawyers advising Ligand were San Diego shareholders Hayden J. Trubitt and Amit Singh.

Please enable JavaScript, then refresh this page. JavaScript is required on this site.